<DOC>
	<DOC>NCT01580748</DOC>
	<brief_summary>There is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. Roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable COPD. We hypothesized that Roflumilast might be effective in symptomatic bronchiectasis patients</brief_summary>
	<brief_title>Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Bronchiectasis</mesh_term>
	<criteria>Bronchiectasis on CT chronic (&gt;3 months) cough or sputum needs hospitalization life expectancy of less than six months pregnancy or breast feeding history of acute respiratory infection within 4 weeks history of taking antibiotics within 4 weeks active hemoptysis %predicted FEV &lt; 30% severe liver disease (Child Pugh Class B or C)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>